NASDAQ:HRTX Heron Therapeutics (HRTX) Stock Price, News & Analysis → Central Bank Gold Heist In Progress (From Colonial Metals) (Ad) Free HRTX Stock Alerts $2.96 -0.10 (-3.27%) (As of 03/18/2024 ET) Add Compare Share Share Today's Range$2.92▼$3.0850-Day Range$2.09▼$3.0652-Week Range$0.50▼$3.22Volume2.04 million shsAverage Volume3.30 million shsMarket Capitalization$444.98 millionP/E RatioN/ADividend YieldN/APrice Target$7.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Heron Therapeutics alerts: Email Address Heron Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside153.4% Upside$7.50 Price TargetShort InterestBearish16.32% of Shares Sold ShortDividend StrengthN/ASustainability-1.96Upright™ Environmental ScoreNews Sentiment0.65Based on 15 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.22) to ($0.09) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.09 out of 5 starsMedical Sector196th out of 947 stocksPharmaceutical Preparations Industry88th out of 435 stocks 3.5 Analyst's Opinion Consensus RatingHeron Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $7.50, Heron Therapeutics has a forecasted upside of 153.4% from its current price of $2.96.Amount of Analyst CoverageHeron Therapeutics has only been the subject of 1 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted16.32% of the outstanding shares of Heron Therapeutics have been sold short.Short Interest Ratio / Days to CoverHeron Therapeutics has a short interest ratio ("days to cover") of 8.8.Change versus previous monthShort interest in Heron Therapeutics has recently decreased by 0.37%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldHeron Therapeutics does not currently pay a dividend.Dividend GrowthHeron Therapeutics does not have a long track record of dividend growth. Previous Next 4.2 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreHeron Therapeutics has received a 61.27% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Antiemetics and antinauseants (A04)", "Bupivacaine", and "Clinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Heron Therapeutics is -1.96. Previous Next 3.1 News and Social Media Coverage News SentimentHeron Therapeutics has a news sentiment score of 0.65. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 15 news articles for Heron Therapeutics this week, compared to 2 articles on an average week.Search Interest26 people have searched for HRTX on MarketBeat in the last 30 days. This is an increase of 13% compared to the previous 30 days.MarketBeat Follows13 people have added Heron Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 86% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Heron Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.40% of the stock of Heron Therapeutics is held by insiders.Percentage Held by Institutions81.77% of the stock of Heron Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Heron Therapeutics are expected to grow in the coming year, from ($0.22) to ($0.09) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Heron Therapeutics is -3.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Heron Therapeutics is -3.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioHeron Therapeutics has a P/B Ratio of 26.91. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaLike Tiny Crypto Retirement FundsThe crypto bull market is about to blast off. Bitcoin and Ethereum are surging. But so are tiny altcoins that could be so profitable… They're like tiny crypto retirement funds. Click here and see how to get a copy. About Heron Therapeutics Stock (NASDAQ:HRTX)Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; HTX-019, an investigational agent for the prevention of postoperative nausea and vomiting; and HTX-034 for postoperative pain management, as well as is in Phase Ib/II clinical study in patients undergoing bunionectomy. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.Read More HRTX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart HRTX Stock News HeadlinesMarch 16, 2024 | ca.finance.yahoo.comHRTX Apr 2024 1.500 callMarch 14, 2024 | finance.yahoo.comHeron Therapeutics Full Year 2023 Earnings: Beats ExpectationsMarch 19, 2024 | InvestorPlace (Ad)They said crypto was dead. It went up 100X.Bitcoin’s haters are out again. Despite the price doubling in the last six months alone… That hasn’t stopped the experts from piling on. Warren Buffett’s right-hand man Charlie Munger called crypto investors “idiots” in one of his last interviews. JPMorgan CEO Jamie Dimon, recently called Bitcoin a “pet rock” and “a hyped-up fraud.” But when it comes to cryptos, these are exactly the people you shouldn’t listen to. They’ve predicted crypto’s demise for years.March 14, 2024 | americanbankingnews.comHeron Therapeutics (NASDAQ:HRTX) Price Target Increased to $5.00 by Analysts at Needham & Company LLCMarch 14, 2024 | marketwatch.comHeron Therapeutics Soars After 4Q Earnings BeatMarch 13, 2024 | theglobeandmail.comBiotech Finds Mid-Week Success Following Q4 Earnings ReleaseMarch 13, 2024 | markets.businessinsider.comWhy Is Postoperative Pain Focused Heron Therapeutics Stock Trading Higher On Wednesday?March 13, 2024 | finance.yahoo.comHeron Therapeutics, Inc. (NASDAQ:HRTX) Q4 2023 Earnings Call TranscriptMarch 19, 2024 | InvestorPlace (Ad)They said crypto was dead. It went up 100X.Bitcoin’s haters are out again. Despite the price doubling in the last six months alone… That hasn’t stopped the experts from piling on. Warren Buffett’s right-hand man Charlie Munger called crypto investors “idiots” in one of his last interviews. JPMorgan CEO Jamie Dimon, recently called Bitcoin a “pet rock” and “a hyped-up fraud.” But when it comes to cryptos, these are exactly the people you shouldn’t listen to. They’ve predicted crypto’s demise for years.March 13, 2024 | finance.yahoo.comQ4 2023 Heron Therapeutics Inc Earnings CallMarch 12, 2024 | finance.yahoo.comHeron Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Corporate UpdatesMarch 12, 2024 | finance.yahoo.comHeron Therapeutics Inc (HRTX) Exceeds Full-Year Revenue Guidance for 2023March 11, 2024 | msn.comHeron Therapeutics Q4 2023 Earnings PreviewMarch 11, 2024 | markets.businessinsider.comWhat Wall Street expects from Heron Therapeutics's earningsMarch 11, 2024 | benzinga.comPreview: Heron Therapeutics's EarningsFebruary 28, 2024 | finance.yahoo.comHeron Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results On Tuesday, March 12, 2024February 28, 2024 | prnewswire.comHeron Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results On Tuesday, March 12, 2024February 24, 2024 | msn.comHeron Therapeutics (HRTX) Price Target Increased by 18.52% to 6.80February 22, 2024 | benzinga.comHeron Therapeutics Stock (NASDAQ:HRTX), Short Interest ReportFebruary 17, 2024 | finance.yahoo.comHRTX Mar 2024 0.500 callFebruary 16, 2024 | finance.yahoo.comInvestors in Heron Therapeutics (NASDAQ:HRTX) from five years ago are still down 90%, even after 23% gain this past weekFebruary 12, 2024 | finance.yahoo.comOcular Therapeutix (OCUL) Surges 12.9%: Is This an Indication of Further Gains?February 6, 2024 | finance.yahoo.comAll You Need to Know About Heron Therapeutics (HRTX) Rating Upgrade to Strong BuyJanuary 25, 2024 | finance.yahoo.comHeron (HRTX) Gains 19% on FDA Nod for Zynrelef Label ExpansionJanuary 24, 2024 | marketwatch.comHeron Therapeutics Shares Rise 15% After FDA Approves Expanded Use of ZynrelefJanuary 24, 2024 | markets.businessinsider.comHeron Therapeutics: Strong Buy on Zynrelef’s Market Expansion and Strategic CollaborationsJanuary 24, 2024 | msn.comPremarket Heats Up For Biotech Before Opening BellSee More Headlines Receive HRTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Heron Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/23/2023Today3/18/2024Next Earnings (Estimated)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:HRTX CUSIPN/A CIK818033 Webwww.herontx.com Phone(858) 251-4400Fax650-365-6490Employees203Year Founded1983Price Target and Rating Average Stock Price Target$7.50 High Stock Price Target$10.00 Low Stock Price Target$5.00 Potential Upside/Downside+153.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.86) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-182,020,000.00 Net Margins-87.02% Pretax Margin-87.02% Return on EquityN/A Return on Assets-50.61% Debt Debt-to-Equity RatioN/A Current Ratio2.37 Quick Ratio1.91 Sales & Book Value Annual Sales$127.04 million Price / Sales3.50 Cash FlowN/A Price / Cash FlowN/A Book Value$0.11 per share Price / Book26.91Miscellaneous Outstanding Shares150,330,000Free Float140,708,000Market Cap$444.98 million OptionableOptionable Beta1.68 Social Links These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesMr. Craig Alexander Collard (Age 58)CEO & Director Ms. Ira Duarte (Age 55)Executive VP & CFO Ms. Lisa Peraza (Age 47)VP & Chief Accounting Officer Comp: $474.1kDr. Thomas B. Ottoboni Ph.D. (Age 65)Chief Scientific Officer and Senior VP of Pharmaceutical & Translational Sciences Mr. Ryan CraigVice President of MarketingMr. Sean T. Ristine (Age 54)Senior Vice President of Human Resources Dr. Chris M. Storgard (Age 58)Chief Medical Officer Mr. Robert Sullivan (Age 46)Senior VP of Oncology Care Franchise & Commercial Operations Dr. William P. Forbes Pharm. D. (Age 62)Pharm.D., Executive VP & Chief Development Officer Jeff CohnExecutive Director, Assistant General Counsel & Assistant SecretaryMore ExecutivesKey CompetitorsInozyme PharmaNASDAQ:INZYAmarinNASDAQ:AMRNNeoleukin TherapeuticsNASDAQ:NLTXHarrow HealthNASDAQ:HROWAtea PharmaceuticalsNASDAQ:AVIRView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Bought 169,632 shares on 3/11/2024Ownership: 5.557%Goldman Sachs Group Inc.Bought 378,845 shares on 3/1/2024Ownership: 0.656%Virtu Financial LLCBought 25,608 shares on 2/26/2024Ownership: 0.027%GSA Capital Partners LLPBought 339,448 shares on 2/16/2024Ownership: 0.226%Price T Rowe Associates Inc. MDBought 5,127 shares on 2/16/2024Ownership: 0.017%View All Insider TransactionsView All Institutional Transactions HRTX Stock Analysis - Frequently Asked Questions Should I buy or sell Heron Therapeutics stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Heron Therapeutics in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" HRTX shares. View HRTX analyst ratings or view top-rated stocks. What is Heron Therapeutics' stock price target for 2024? 3 equities research analysts have issued 1-year price targets for Heron Therapeutics' stock. Their HRTX share price targets range from $5.00 to $10.00. On average, they anticipate the company's stock price to reach $7.50 in the next twelve months. This suggests a possible upside of 153.4% from the stock's current price. View analysts price targets for HRTX or view top-rated stocks among Wall Street analysts. How have HRTX shares performed in 2024? Heron Therapeutics' stock was trading at $1.70 at the beginning of 2024. Since then, HRTX stock has increased by 74.1% and is now trading at $2.96. View the best growth stocks for 2024 here. When is Heron Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our HRTX earnings forecast. How were Heron Therapeutics' earnings last quarter? Heron Therapeutics, Inc. (NASDAQ:HRTX) released its quarterly earnings data on Thursday, March, 23rd. The biotechnology company reported ($0.17) EPS for the quarter, beating analysts' consensus estimates of ($0.25) by $0.08. The biotechnology company earned $30 million during the quarter, compared to analysts' expectations of $27.24 million. The company's revenue for the quarter was up 44.9% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.54) EPS. What ETFs hold Heron Therapeutics' stock? ETFs with the largest weight of Heron Therapeutics (NASDAQ:HRTX) stock in their portfolio include Jacob Forward ETF (JFWD) and Invesco Nasdaq Future Gen 200 ETF (QQQS).Simplify Propel Opportunities ETF (SURI). What guidance has Heron Therapeutics issued on next quarter's earnings? Heron Therapeutics updated its FY 2024 earnings guidance on Tuesday, March, 12th. The company provided EPS guidance of for the period. The company issued revenue guidance of $138.0 million-$158.0 million, compared to the consensus revenue estimate of $139.1 million. What other stocks do shareholders of Heron Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Heron Therapeutics investors own include Micron Technology (MU), Pfizer (PFE), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), NVIDIA (NVDA), Editas Medicine (EDIT), Immunomedics (IMMU), bluebird bio (BLUE), AT&T (T) and Amarin (AMRN). Who are Heron Therapeutics' major shareholders? Heron Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (5.56%), Vanguard Group Inc. (5.56%), Franklin Resources Inc. (4.27%), Palisade Capital Management LP (2.43%), JW Asset Management LLC (1.53%) and Orchard Capital Management LLC (1.49%). Insiders that own company stock include Adam Morgan, Craig A Collard, Craig A Johnson, Ira Duarte, Kimberly Manhard, Waage Christian and William P Forbes. View institutional ownership trends. How do I buy shares of Heron Therapeutics? Shares of HRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Does Heron Therapeutics have any subsidiaries? The following companies are subsidiares of Heron Therapeutics: Heron Therapeutics B.V..Read More This page (NASDAQ:HRTX) was last updated on 3/19/2024 by MarketBeat.com Staff From Our Partners8,788% Return Predicted For THIS Crypto (already up 40% in 6 months)Paradigm PressCentral Bank Gold Heist In ProgressColonial MetalsLike Tiny Crypto Retirement FundsCrypto 101 MediaThe AI Bottleneck No One is Talking AboutThe Bull ReportMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceSHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceThe world’s greatest investmentPorter & CompanyBuy this small stock before coming AI Tidal WaveChaikin Analytics Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Heron Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.